Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.36 |
| ▸ | CHRNG | P07510 | 3/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.36 |
| ▸ | CHRND | Q07001 | 3/20 | 0.36 |
| ▸ | ACE | P12821 | 4/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19542059 | 0.93 | REN (0.46) | RENCYP3A4SSTR2CHRNB2CHRNB4 | |
| SCHEMBL16645013 | 0.92 | REN (0.40) | RENCYP3A4SSTR2ACEACE2 | |
| SCHEMBL16645055 | 0.91 | CYP3A4 (0.44) | RENCYP3A4SSTR2FOLH1 | |
| SCHEMBL19750458 | 0.90 | REN (0.48) | RENCYP3A4SSTR2CHRNB2CHRNB4 | |
| SCHEMBL25000824 | 0.88 | CYP3A4 (0.40) | RENCYP3A4SSTR2CHRNB2CHRNB4 | |
| SCHEMBL16645135 | 0.87 | REN (0.43) | RENCYP3A4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26535455 | 0.87 | CYP3A4 (0.39) | RENCYP3A4SSTR2ACEACE2 | |
| SCHEMBL26537727 | 0.86 | CYP3A4 (0.44) | RENCYP3A4SSTR2ACEACE2 | |
| SCHEMBL20224794 | 0.86 | CYP3A4 (0.44) | RENCYP3A4SSTR2FOLH1 | |
| SCHEMBL20224792 | 0.86 | CYP3A4 (0.45) | RENCYP3A4SSTR2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | REN 4162/4885CYP3A4 3343/4885SSTR2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.